Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC)[1].
Molecular Weight:
(146.4 kDa)
Purity:
95.00
CAS Number:
[1031360-18-5]
Target:
LPL Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted